Clare Cruickshank - Concepedia

Author

Clare Cruickshank

Institute of Cancer Research

Also Known As

Clare A. Cruickshank, Clare Cruickshank, Cruickshank, Clare

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Clatterbridge Cancer Centre NHS Foundation Trust Royal Marsden NHS Foundation Trust Cardiff University Velindre Cancer Centre

About

Clare Cruickshank is an author at Institute of Cancer Research specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	205
2	Health Sciences	4	4	95
3	Diagnostic Sciences	1	1	24
4	Immunology	1	1	80
5	Pathology	1	1	17

Clare Cruickshank

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial David P. Dearnaley, Isabel Syndikus, Helen Mossop, The Lancet Oncology	2016	1.3K
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Douglas Brand, Alison Tree, Peter Ostler, The Lancet Oncology	2019	519
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Anna Wilkins, Helen Mossop, Isabel Syndikus, The Lancet Oncology	2015	149
A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti–Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug Astrid Mayer, Roslyn J. Francis, Surinder K. Sharma, Clinical Cancer Research NanotherapeuticsProdrug ActivationImmunologyBiological TherapyImmunotherapeutics	2006	80
PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018) Isabel Syndikus, Clare Cruickshank, John Staffurth, Clinical and Translational Radiation Oncology	2020	49
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer Julia Murray, Clare Griffin, S. Gulliford, Radiotherapy and Oncology	2019	48
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial James M. Wilson, David P. Dearnaley, Isabel Syndikus, International Journal of Radiation OncologyBiologyPhysics	2018	43
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016) John Staffurth, Joanne Haviland, Anna Wilkins, European Urology Oncology	2021	38
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004) John D. Kelly, Wei Shen Tan, Núria Porta, European Urology UrologyTransitional Cell CarcinomaGenitourinary CancerMedicineClinical Trials	2018	36
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial Julia Murray, S. Gulliford, Clare Griffin, Clinical and Translational Radiation Oncology	2019	32

Page 1